Trial Profile

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SEL 212 (Primary) ; Pegloticase
Indications Gout; Gouty arthritis
Focus Therapeutic Use
Acronyms COMPARE
Sponsors Selecta Biosciences

Most Recent Events

14 Jul 2023 Results published in the Rheumatology
30 Sep 2020 According to a Selecta Biosciences media release, the company will held a conference call on 30th September to discuss the COMPARE study.
30 Sep 2020 According to a Selecta Biosciences media release, a full analysis of safety signals, including gout flare incidence and severity, awaits evaluation of the full data set and will be reported together with the full efficacy analysis at a later medical meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com